Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q3 2024 Earnings Conference Call October 31, 2024 8:30 AM ET Company Participants Ryan Crowe - SVP, IR and Strategic Analysis Leonard Schleifer - Board Co-Chair, Co-Founder, President and CEO George Yancopoulos - Board Co-Chair, Co-Founder, President and Chief Scientific Officer Marion McCourt - EVP, Commercial Chris Fenimore - SVP, Finance and CFO Conference Call Participants Taylor Hanley - JPMorgan Tyler Van Buren - TD Cowen Brian Abrahams - RBC Capital Marke ...

Regeneron (REGN) reported $3.72 billion in revenue for the quarter ended September 2024, representing a year-over-year increase of 10.7%. EPS of $12.46 for the same period compares to $11.59 a year ago.The reported revenue represents a surprise of +1.31% over the Zacks Consensus Estimate of $3.67 billion. With the consensus EPS estimate being $11.75, the EPS surprise was +6.04%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determ ...

Regeneron Pharmaceuticals, Inc. (REGN) reported better-than-expected third-quarter results despite lower sales from its lead drug, Eylea. Revenues climbed 11% to $3.72 billion, driven by growth in Eylea HD sales, profits from blockbuster asthma drug Dupixent and oncology drug Libtayo. The top line beat the Zacks Consensus Estimate of $3.67 billion.Higher revenues drove the bottom line as well. Adjusted earnings per share (EPS) of $12.46 beat the Zacks Consensus Estimate of $11.75 and were up 8% from the yea ...

Regeneron (REGN) came out with quarterly earnings of $12.46 per share, beating the Zacks Consensus Estimate of $11.75 per share. This compares to earnings of $11.59 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 6.04%. A quarter ago, it was expected that this biopharmaceutical company would post earnings of $10.57 per share when it actually produced earnings of $11.56, delivering a surprise of 9.37%.Over the last four quarter ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 000-19034 REGENERON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) New York ...

Exhibit 99.1 REGENERON Press Release Regeneron Reports Third Quarter 2024 Financial and Operating Results • Third quarter 2024 revenues increased 11% to $3.72 billion versus third quarter 2023 • Third quarter 2024 Dupixent global net sales (recorded by Sanofi) increased 23% to $3.82 billion versus third quarter 2023 • Third quarter 2024 U.S. net sales for EYLEA HD and EYLEA increased 3% versus third quarter 2023 to $1.54 billion, including $392 million from EYLEA HD • Third quarter 2024 Libtayo global net s ...

Third quarter 2024 revenues increased 11% to $3.72 billion versus third quarter 2023Third quarter 2024 Dupixent® global net sales (recorded by Sanofi) increased 23% to $3.82 billion versus third quarter 2023Third quarter 2024 U.S. net sales for EYLEA HD® and EYLEA® increased 3% versus third quarter 2023 to $1.54 billion, including $392 million from EYLEA HDThird quarter 2024 Libtayo® global net sales increased 24% to $289 million versus third quarter 2023Third quarter 2024 GAAP diluted EPS increased 30% to ...

Biotech giant Regeneron Pharmaceuticals, Inc. (REGN) is slated to report third-quarter results on Oct. 31, 2024. The Zacks Consensus Estimate for revenues is pegged at $3.67 billion, while the same for earnings is pinned at $11.75 per share. Find the latest EPS estimates and surprises on Zacks Earnings Calendar. REGN Faces Decline in Eylea Sales, Dupixent Fuels Growth Regeneron is currently facing challenges for its lead drug, Eylea, which is its primary growth engine. A significant chunk of Regeneron's rev ...

The biotech sector represents companies developing innovative treatments and therapies using biological processes. These firms range from early-stage research companies to established pharmaceutical developers. Biotech stocks offer investment opportunities in companies working on groundbreaking medical solutions. The sector spans various therapeutic areas, from cancer treatments to rare diseases. Investing in biotech stocks can provide exposure to potentially revolutionary medical breakthroughs. Successful ...

Dupixent significantly reduced itch and hive activity from baseline; 41% of patients achieved well-controlled disease status Confirmatory data to support U.S. regulatory resubmission by year-end; if approved, Dupixent would be the first new targeted treatment for people living with chronic spontaneous urticaria in more than 10 years More than 300,000 people in the U.S. suffer from chronic spontaneous urticaria that is inadequately controlled by antihistamines TARRYTOWN, N.Y. and PARIS, Oct. 24, 2024 (GLOBE ...